Sinco Pharmaceuticals Holdings Limited (06833) submitted its monthly return for the period ended 28 February 2026. The authorized share capital remained at 10,000,000,000 ordinary shares, each with a par value of HKD 0.0001, amounting to HKD 1.00 million in total.
The total number of issued shares stood at 2.03 billion with no treasury shares and no changes during the reporting period. Public float requirements were confirmed to be in compliance. The share option scheme, adopted on 26 May 2025, has 203.29 million shares available for potential issuance, with no new shares issued under the scheme during February 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments